Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won a £1.3 million contract as the cognitive assessment partner for a schizophrenia trial. Revenue from the contract is expected to be booked over the next three years. This is the fourth schizophrenia trial Cambridge Cognition has secured with this pharmaceutical client in seven months. The first three were announced by the Company on 1 September 2020 in a £2 million contract.
Cognitive impairment is a core feature of schizophrenia, with deficits frequently observed in memory, attention and executive functions. Impressed by the high degree of sensitivity CANTABTM cognitive assessments demonstrate in measuring these distinct processes and the quality of service the Company delivers, Cambridge Cognition has been named as the cognitive assessment provider for the fourth trial in the series.
Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:
“Schizophrenia affects more than 20 million people worldwide and we are pleased to be strengthening our relationship with a company that recognises the importance of sensitive and accurate cognitive assessment in developing effective therapeutics for the disorder. This quick succession of unusually large contracts with the same pharmaceutical company is a testament to the excellent customer experience and high-quality products Cambridge Cognition delivers.”
